Prothena Corp Public (PRTA) Long-Term Deferred Tax (2012 - 2025)
Prothena Corp Public (PRTA) posted quarterly Long-Term Deferred Tax of $44.9 million for Q1 2025, up 22.46% year-over-year from $36.7 million in Q1 2024, and up 3.87% quarter-over-quarter from $43.2 million in Q4 2024.
Prothena Corp Public (PRTA) Long-Term Deferred Tax (2012 - 2025) Analysis & Trends
Prothena Corp Public's Long-Term Deferred Tax history runs 14 years deep, the most recent figure standing at $44.9 million for Q1 2025.
- In Q1 2025, Long-Term Deferred Tax rose 22.46% year-over-year to $44.9 million; the TTM figure through Mar 2025 stood at $44.9 million (up 22.46% YoY), while the FY2024 annual figure was $43.2 million, up 27.58% from the prior year.
- Long-Term Deferred Tax for Q1 2025 stood at $44.9 million, up from $43.2 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $44.9 million in Q1 2025, with the low at $6.4 million in Q2 2021.
- The 5-year median for Long-Term Deferred Tax is $21.4 million (2023), against an average of $23.4 million.
- The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax sank 43.57% in 2021, then soared 157.45% in 2022.
- Prothena Corp Public's Long-Term Deferred Tax stood at $7.1 million in 2021, then jumped by 157.45% to $18.2 million in 2022, then surged by 86.18% to $33.9 million in 2023, then rose by 27.58% to $43.2 million in 2024, then advanced by 3.87% to $44.9 million in 2025.
- Business Quant data shows PRTA's Long-Term Deferred Tax at $44.9 million in Q1 2025, $43.2 million in Q4 2024, and $41.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 44.91 Mn |
| Dec 31, 2024 | 43.24 Mn |
| Sep 30, 2024 | 41.00 Mn |
| Jun 30, 2024 | 39.48 Mn |
| Mar 31, 2024 | 36.68 Mn |
| Dec 31, 2023 | 33.89 Mn |
| Sep 30, 2023 | 29.92 Mn |
| Jun 30, 2023 | 25.94 Mn |
| Mar 31, 2023 | 21.43 Mn |
| Dec 31, 2022 | 18.20 Mn |
| Sep 30, 2022 | 14.97 Mn |
| Jun 30, 2022 | 11.96 Mn |
| Mar 31, 2022 | 9.59 Mn |
| Dec 31, 2021 | 7.07 Mn |
| Sep 30, 2021 | 6.50 Mn |
| Jun 30, 2021 | 6.43 Mn |
| Mar 31, 2021 | 7.02 Mn |
| Dec 31, 2020 | 11.64 Mn |
| Sep 30, 2020 | 11.52 Mn |
| Jun 30, 2020 | 11.02 Mn |